Device Endovascular

Paradise Renal Denervation System

Payments companies reported to CMS as associated with Paradise Renal Denervation System. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$169Kassociated payments (2023-2025)
1,329clinicians with associated payments
1company reporting

By year

2024 $169K

Payments reported as associated with Paradise Renal Denervation System, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Interventional Cardiology $73K
Cardiovascular Disease $32K
Internal Medicine $20K
Nephrology (Internal Medicine) $8,389
Family $7,317
Physician Assistant $5,693

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Paradise Renal Denervation System

These are the largest totals companies reported as associated with Paradise Renal Denervation System. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Taisei Kobayashi Philadelphia, PA Interventional Cardiology $9,288.27
Wayne Batchelor Falls Church, VA Interventional Cardiology $8,923.93
Thomas Todoran Pawleys Island, SC Interventional Cardiology $8,181.15
Michael Bloch Reno, NV Internal Medicine $7,226.86
Luke Laffin Chicago, IL Internal Medicine $7,101.12
Tiffany Randolph Greensboro, NC Cardiovascular Disease $6,809.26
Aravinda Nanjundappa Beckley, WV Interventional Cardiology $4,428.73
Debbie Cohen Stein Philadelphia, PA Nephrology (Internal Medicine) $4,319.79
Wissam Gharib Morgantown, WV Interventional Cardiology $4,142.14
Florian Rader West Hollywood, CA Cardiovascular Disease $3,785.47

Prescribed Paradise Renal Denervation System?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.